Search

Your search keyword '"Autran, Brigitte"' showing total 994 results
Start Over Author "Autran, Brigitte"
994 results on '"Autran, Brigitte"'

1. Clonal succession after prolonged antiretroviral therapy rejuvenates CD8+ T cell responses against HIV-1

Author

White, Eoghann, Papagno, Laura, Samri, Assia, Sugata, Kenji, Hejblum, Boris, Henry, Amy R., Rogan, Daniel C., Darko, Samuel, Recordon-Pinson, Patricia, Dudoit, Yasmine, Llewellyn-Lacey, Sian, Chakrabarti, Lisa A., Buseyne, Florence, Migueles, Stephen A., Price, David A., Andreola, Marie-Aline, Satou, Yorifumi, Thiebaut, Rodolphe, Katlama, Christine, Autran, Brigitte, Douek, Daniel C., and Appay, Victor

Published
2024
Full Text
View/download PDF

2. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages

Author

Driouich, Jean-Sélim, Cochin, Maxime, Lingas, Guillaume, Luciani, Léa, Baronti, Cécile, Bernadin, Ornéllie, Gilles, Magali, Villarroel, Paola Mariela Saba, Moureau, Grégory, Petit, Paul-Rémi, Dupont, Axelle, Izopet, Jacques, Kamar, Nassim, Autran, Brigitte, Paintaud, Gilles, Caillard, Sophie, le Bourgeois, Amandine, Richez, Christophe, Couzi, Lionel, Xhaard, Aliénor, Marjanovic, Zora, Avouac, Jerome, Jacquet, Caroline, Anglicheau, Dany, Cheminant, Morgane, Nguyen, Stéphanie, Terrier, Benjamin, Gottenberg, Jacques Eric, Besson, Caroline, Letrou, Sophie, Tine, Josephine, Basilua, Joe Miantezila, Angoulvant, Denis, Tardivon, Coralie, Blancho, Gilles, Martin-Blondel, Guillaume, Yazdanpanah, Yazdan, Mentré, France, Lévy, Vincent, Touret, Franck, Guedj, Jérémie, de Lamballerie, Xavier, and Nougairède, Antoine

Published
2024
Full Text
View/download PDF

4. Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments

Author

Baron, Marine, primary, Labreche, Karim, additional, Veyri, Marianne, additional, Désiré, Nathalie, additional, Bouzidi, Amira, additional, Seck-Thiam, Fatou, additional, Charlotte, Frédéric, additional, Rousseau, Alice, additional, Morin, Véronique, additional, Nakid-Cordero, Cécilia, additional, Abbar, Baptiste, additional, Picca, Alberto, additional, Le Cann, Marie, additional, Balegroune, Noureddine, additional, Gauthier, Nicolas, additional, Theodorou, Ioannis, additional, Touat, Mehdi, additional, Morel, Véronique, additional, Bielle, Franck, additional, Samri, Assia, additional, Alentorn, Agusti, additional, Sanson, Marc, additional, Roos-Weil, Damien, additional, Haioun, Corinne, additional, Poullot, Elsa, additional, De Septenville, Anne Langlois, additional, Davi, Frédéric, additional, Guihot, Amélie, additional, Boelle, Pierre-Yves, additional, Leblond, Véronique, additional, Coulet, Florence, additional, Spano, Jean-Philippe, additional, Choquet, Sylvain, additional, Autran, Brigitte, additional, and Study group, IDeATIon, additional

Published
2024
Full Text
View/download PDF

5. Comprehensive analysis of early T cell responses to acute Zika Virus infection during the first epidemic in Bahia, Brazil

Author

Samri, Assia, primary, Bandeira, Antonio Carlos, additional, Gois, Luana Leandro, additional, Silva, Carlos Gustavo Regis, additional, Rousseau, Alice, additional, Corneau, Aurelien, additional, Tarantino, Nadine, additional, Maucourant, Christopher, additional, Queiroz, Gabriel Andrade Nonato, additional, Vieillard, Vincent, additional, Yssel, Hans, additional, Campos, Gubio Soares, additional, Sardi, Silvia, additional, Autran, Brigitte, additional, and Rios Grassi, Maria Fernanda, additional

Published
2024
Full Text
View/download PDF

8. Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023).

Author

Van Coillie, Samya, Prévot, Johan, Sánchez-Ramón, Silvia, Lowe, David M., Borg, Michael, Autran, Brigitte, Segundo, Gesmar, Pecoraro, Antonio, Garcelon, Nicolas, Boersma, Cornelis, Silva, Susana L., Drabwell, Jose, Quinti, Isabella, Meyts, Isabelle, Ali, Adli, Burns, Siobhan O., van Hagen, Martin, Pergent, Martine, and Mahlaoui, Nizar

Subjects
PANDEMIC preparedness, PRIMARY immunodeficiency diseases, ARTIFICIAL intelligence, DRUG resistance in microorganisms, CRISIS management
Abstract

The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its second Global Multi-Stakeholders’ Summit, an annual stimulating and forward-thinking meeting uniting experts to anticipate pivotal upcoming challenges and opportunities in the field of primary immunodeficiency (PID). The 2023 summit focused on three key identified discussion points: (i) How can immunoglobulin (Ig) therapy meet future personalized patient needs? (ii) Pandemic preparedness: what’s next for public health and potential challenges for the PID community? (iii) Diagnosing PIDs in 2030: what needs to happen to diagnose better and to diagnose more? Clinician-Scientists, patient representatives and other stakeholders explored avenues to improve Ig therapy through mechanistic insights and tailored Ig preparations/products according to patient-specific needs and local exposure to infectious agents, amongst others. Urgency for pandemic preparedness was discussed, as was the threat of shortage of antibiotics and increasing antimicrobial resistance, emphasizing the need for representation of PID patients and other vulnerable populations throughout crisis and care management. Discussion also covered the complexities of PID diagnosis, addressing issues such as global diagnostic disparities, the integration of patient-reported outcome measures, and the potential of artificial intelligence to increase PID diagnosis rates and to enhance diagnostic precision. These proceedings outline the outcomes and recommendations arising from the 2023 IPOPI Global Multi-Stakeholders’ Summit, offering valuable insights to inform future strategies in PID management and care. Integral to this initiative is its role in fostering collaborative efforts among stakeholders to prepare for the multiple challenges facing the global PID community. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. International AIDS Society global scientific strategy: towards an HIV cure 2016

Author

Deeks, Steven G, Lewin, Sharon R, Ross, Anna Laura, Ananworanich, Jintanat, Benkirane, Monsef, Cannon, Paula, Chomont, Nicolas, Douek, Daniel, Lifson, Jeffrey D, Lo, Ying-Ru, Kuritzkes, Daniel, Margolis, David, Mellors, John, Persaud, Deborah, Tucker, Joseph D, Barre-Sinoussi, Françoise, Alter, Galit, Auerbach, Judith, Autran, Brigitte, Barouch, Dan H, Behrens, Georg, Cavazzana, Marina, Chen, Zhiwei, Cohen, Éric A, Corbelli, Giulio Maria, Eholié, Serge, Eyal, Nir, Fidler, Sarah, Garcia, Laurindo, Grossman, Cynthia, Henderson, Gail, Henrich, Timothy J, Jefferys, Richard, Kiem, Hans-Peter, McCune, Joseph, Moodley, Keymanthri, Newman, Peter A, Nijhuis, Monique, Nsubuga, Moses Supercharger, Ott, Melanie, Palmer, Sarah, Richman, Douglas, Saez-Cirion, Asier, Sharp, Matthew, Siliciano, Janet, Silvestri, Guido, Singh, Jerome, Spire, Bruno, Taylor, Jeffrey, Tolstrup, Martin, Valente, Susana, van Lunzen, Jan, Walensky, Rochelle, Wilson, Ira, and Zack, Jerome

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Good Health and Well Being, Acquired Immunodeficiency Syndrome, Goals, HIV Infections, Humans, International Cooperation, Organizational Objectives, Research, Societies, Medical, International AIDS Society Towards a Cure Working Group, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a global population of more than 35 million people living with HIV, there is intense interest in developing a cure for HIV infection. The International AIDS Society convened a group of international experts to develop a scientific strategy for research towards an HIV cure. This Perspective summarizes the group's strategy.

Published
2016

11. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects

Author

Gach, Johannes S, Gorlani, Andrea, Dotsey, Emmanuel Y, Becerra, Juan C, Anderson, Chase TM, Berzins, Baiba, Felgner, Philip L, Forthal, Donald N, Deeks, Steven G, Wilkin, Timothy J, Casazza, Joseph P, Koup, Richard A, Katlama, Christine, Autran, Brigitte, Murphy, Robert L, and Achenbach, Chad J

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Clinical Trials and Supportive Activities, Vaccine Related (AIDS), Infectious Diseases, HIV/AIDS, Sexually Transmitted Infections, Biotechnology, Clinical Research, Vaccine Related, Prevention, Immunization, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Infection, Good Health and Well Being, AIDS Vaccines, Adenoviridae, Antibodies, Neutralizing, Antibodies, Viral, CD4-Positive T-Lymphocytes, Female, HIV Antibodies, HIV Infections, HIV-1, Human Immunodeficiency Virus Proteins, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, DNA, General Science & Technology
Abstract

Little is known about the humoral immune response against DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine among HIV-infected patients on long-term suppressive antiretroviral therapy (ART). Previous studies emphasized cellular immune responses; however, current research suggests both cellular and humoral responses are likely required for a successful therapeutic vaccine. Thus, we aimed to understand antibody response and function induced by vaccination of ART-treated HIV-1-infected patients with immune recovery. All subjects participated in EraMune 02, an open-label randomized clinical trial of ART intensification followed by a six plasmid DNA prime (envA, envB, envC, gagB, polB, nefB) and rAd5 boost HIV vaccine with matching inserts. Antibody binding levels were determined with a recently developed microarray approach. We also analyzed neutralization efficiency and antibody-dependent cellular cytotoxicity (ADCC). We found that the DNA prime-rAd5 boost vaccine induced a significant cross-clade HIV-specific antibody response, which correlated with antibody neutralization efficiency. However, despite the increase in antibody binding levels, the vaccine did not significantly stimulate neutralization or ADCC responses. This finding was also reflected by a lack of change in total CD4+ cell associated HIV DNA in those who received the vaccine. Our results have important implications for further therapeutic vaccine design and administration, especially in HIV-1 infected patients, as boosting of preexisting antibody responses are unlikely to lead to clearance of latent proviruses in the HIV reservoir.

Published
2016

13. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial

Author

Achenbach, Chad J, Assoumou, Lambert, Deeks, Steven G, Wilkin, Timothy J, Berzins, Baiba, Casazza, Joseph P, Lambert-Niclot, Sidonie, Koup, Richard A, Costagliola, Dominique, Calvez, Vincent, Katlama, Christine, Autran, Brigitte, Murphy, Robert L, and team, for the EraMune 02 study

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Minority Health, Sexually Transmitted Infections, Biotechnology, Vaccine Related, Infectious Diseases, Clinical Trials and Supportive Activities, HIV/AIDS, Prevention, Clinical Research, Immunization, 6.1 Pharmaceuticals, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, AIDS Vaccines, Adenoviridae, Adolescent, Adult, Aged, Anti-HIV Agents, CD4 Lymphocyte Count, Female, HIV Infections, HIV-1, Humans, Immunization, Secondary, Leukocytes, Mononuclear, Male, Middle Aged, Treatment Outcome, Vaccination, Vaccines, DNA, Viral Load, Young Adult, EraMune 02 study team, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundAchievement of a cure for HIV infection might need reactivation of latent virus and improvement of HIV-specific immunity. As an initial step, in this trial we assessed the effect of antiretroviral therapy intensification and immune modulation with a DNA prime and recombinant adenovirus 5 (rAd5) boost vaccine.MethodsIn this multicentre, randomised, open-label, non-comparative, phase 2 clinical trial, we enrolled eligible adults 18-70 years of age with chronic HIV-1 infection on suppressive antiretroviral therapy with current CD4 count of at least 350 cells per μL and HIV DNA between 10 and 1000 copies per 10(6) peripheral blood mononuclear cells. After an 8 week lead-in of antiretroviral intensification therapy (standard dose raltegravir and dose-adjusted maraviroc based on baseline antiretroviral therapy), patients were randomly assigned (1:1) to receive antiretroviral therapy intensification alone or intensification plus injections of HIV DNA prime vaccine (4 mg VRC-HIVDNA016-00-VP) at weeks 8, 12, and 16, followed by HIV rAd5 boost vaccine (10(10) particle units of VRC-HIVADV014-00-VP) at week 32. Randomisation was computer generated in permuted blocks of six and was stratified by study site. The primary endpoint was a 0·5 log10 or greater decrease in HIV DNA in peripheral blood mononuclear cells at week 56. This study is registered with ClinicalTrials.gov, number NCT00976404.FindingsBetween Nov 29, 2010, and Oct 28, 2011, we enrolled 28 eligible patients from three academic HIV clinics in the USA. After the 8 week lead-in of antiretroviral intensification therapy, 14 patients were randomly assigned to continue antiretroviral therapy intensification alone and 14 to intensification plus vaccine. Enrolled participants had median CD4 count of 636 cells per μL, median HIV DNA 170 copies per 10(6) peripheral blood mononuclear cells, and duration of antiretroviral therapy of 13 years. The median amount of HIV DNA did not change significantly between baseline and week 56 in the antiretroviral therapy intensification plus vaccine group. One participant in the antiretroviral therapy intensification alone group reached the primary endpoint, with 0·55 log10 decrease in HIV DNA in peripheral blood mononuclear cells. Both treatments were well tolerated. No severe or systemic reactions to vaccination occurred, and five serious adverse events were recorded during the study, most of which resolved spontaneously or were judged unrelated to study treatments.InterpretationAntiretroviral therapy intensification followed by DNA prime and rAd5 boost vaccine did not significantly increase HIV expression or reduce the latent HIV reservoir. A multifaceted approach that includes stronger activators of HIV expression and novel immune modulators will probably be needed to reduce the latent HIV reservoir and allow for long-term control in patients off antiretroviral therapy.FundingObjectif Recherche Vaccin SIDA (ORVACS).

Published
2015

16. How to improve vaccine acceptability (evaluation, pharmacovigilance, communication, public health, mandatory vaccination, fears and beliefs)

Author

Autran, Brigitte, Béhier, Jehan-Michel, Borel, Thomas, Bresse, Xavier, Chêne, Geneviève, Courcier, Soizic, Dufour, Véronique, Faurisson, François, Gagneur, Arnaud, Gelpi, Odile, Gérald, Franck, Kheloufi, Farid, Koeck, Jean-Louis, Lamarque-Garnier, Véronique, Lery, Telma, Ménin, Géraldine, Molimard, Mathieu, Opinel, Annick, Roger, Claire, Rouby, Franck, Schuck, Stéphane, Simon, Laurent, Soubeyrand, Benoît, Truchet, Marie-Christine, Dutilleul, Alain, Morel, Jacques, Schilte, Clémentine, and Launay, Odile

Published
2019
Full Text
View/download PDF

17. Comment améliorer l’acceptabilité vaccinale (évaluation, pharmacovigilance, communication, santé publique, obligation vaccinale, peurs et croyances)

Author

Autran, Brigitte, Béhier, Jehan-Michel, Borel, Thomas, Bresse, Xavier, Chêne, Geneviève, Courcier, Soizic, Dufour, Véronique, Faurisson, François, Gagneur, Arnaud, Gelpi, Odile, Gérald, Franck, Kheloufi, Farid, Koeck, Jean-Louis, Lamarque-Garnier, Véronique, Lery, Telma, Ménin, Géraldine, Molimard, Mathieu, Opinel, Annick, Roger, Claire, Rouby, Franck, Schuck, Stéphane, Simon, Laurent, Soubeyrand, Benoît, Truchet, Marie-Christine, Dutilleul, Alain, Morel, Jacques, Schilte, Clémentine, and Launay, Odile

Published
2019
Full Text
View/download PDF

18. A truncated HIV Tat demonstrates potent and specific latency reversal activity

Author

Van Gulck, Ellen, primary, Pardons, Marion, additional, Nijs, Erik, additional, Verheyen, Nick, additional, Dockx, Koen, additional, Van Den Eynde, Christel, additional, Battivelli, Emilie, additional, Vega, Jerel, additional, Florence, Eric, additional, Autran, Brigitte, additional, Archin, Nancie M., additional, Margolis, David M., additional, Katlama, Christine, additional, Hamimi, Chiraz, additional, Van Den Wyngaert, Ilse, additional, Eyassu, Filmon, additional, Vandekerckhove, Linos, additional, and Boden, Daniel, additional

Published
2023
Full Text
View/download PDF

20. Dynamics in HIV-DNA levels over time in HIV controllers

Author

Avettand-Fenoel, Veronique, Bayan, Tatiana, Gardiennet, Elise, Boufassa, Faroudy, Lopez, Pauline, Lecuroux, Camille, Noel, Nicolas, Tremeaux, Pauline, Monceaux, Valerie, Autran, Brigitte, Meyer, Laurence, Saez-Cirion, Asier, Lambotte, Olivier, and Rouzioux, Christine

Subjects
HIV infections -- Development and progression -- Genetic aspects, HIV carriers -- Health aspects, Health
Abstract

Introduction: HIV controllers (HIC) maintain viraemia at low levels without antiretroviral treatment and have small HIV reservoirs. Nevertheless, they are heterogeneous regarding their risk of infection progression. The study of reservoirs can help elucidate this control. This study aimed to explore the factors implicated in the pathogenesis of HIV infection that are potentially associated with HIV reservoirs and their dynamics in HIC. Methods: Individuals living with HIV included in the ANRS-CODEX cohort with at least two HIV-DNA measurements between 2009 and 2016 were selected. The total HIV-DNA levels had been quantified prospectively from blood samples. Mixed-effect linear models estimated the HIV-DNA dynamics over time. Results: The median (interquartile range (IQR)) HIV-DNA level was 1.5 (1.3 to 1.9) log copies/million peripheral blood mononuclear cells at inclusion (n = 202 individuals). These low levels showed heterogeneity among HIC. Lower levels were then associated with the protective HLA-B*27/B*57 alleles and/or lower HIV-RNA level at inclusion, negative hepatitis C virus serology, lower HIV-suppressive capacity of specific CD8 T cells and lower levels of immune activation and inflammation. Interestingly, mathematical modelling of the dynamics of HIV-DNA over time (840 measurements) showed that the number of infected cells decreased in 46% of HIC (follow-up: 47.6 months) and increased in 54% of HIC. A multivariate analysis indicated that HLA-B*27/B*57 alleles, a low level of HIV-RNA and a low level of HIV-DNA at inclusion were markers independently associated with this decrease. Conclusions: These results offer new insights into the mechanisms of long-term control in HIC. In half of HIC, the decrease in HIV-DNA level could be linked to tighter viral control and progressive loss of infected cells. These findings allow the identification of HIC with a low risk of progression who may not need treatment. Keywords: HIV reservoir; HIV controllers; total HIV-DNA; dynamics; long-term follow-up, 1 | INTRODUCTION Human immunodeficiency virus type 1 (HIV-1) controllers (HIC) are a rare group of individuals living with HIV who maintain HIV viraemia at extremely low or even undetectable [...]

Published
2019
Full Text
View/download PDF

21. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Author

Katlama, Christine, Deeks, Steven G, Autran, Brigitte, Martinez-Picado, Javier, van Lunzen, Jan, Rouzioux, Christine, Miller, Michael, Vella, Stefano, Schmitz, Joern E, Ahlers, Jeffrey, Richman, Douglas D, and Sekaly, Rafick P

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, HIV/AIDS, Aetiology, 2.2 Factors relating to the physical environment, Infection, Anti-HIV Agents, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Drug Therapy, Combination, HIV Infections, HIV-1, Humans, RNA, Viral, Receptors, CCR5, Virus Latency, Virus Replication, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.

Published
2013

32. A truncated HIV Tat demonstrates potent and specific latency reversal activity

Author

Gulck, Ellen Van, primary, Pardons, Marion, additional, Nijs, Erik, additional, Verheyen, Nick, additional, Dockx, Koen, additional, Van den Eynde, Christel, additional, Battivelli, Emilie, additional, Vega, Jerel, additional, Florence, Eric, additional, Autran, Brigitte, additional, Archin, Nancie M., additional, Margolis, David M., additional, Katlama, Kristine, additional, Hamimi, Chiraz, additional, Van den Wyngaert, Ilse, additional, Eyassu, Filmon, additional, Vandekerckhove, Linos, additional, and Boden, Daniel, additional

Published
2023
Full Text
View/download PDF

34. Clonal succession after prolonged antiretroviral therapy rejuvenates CD8+T cell responses against HIV-1

Author

White, Eoghann, Papagno, Laura, Samri, Assia, Sugata, Kenji, Hejblum, Boris, Henry, Amy R., Rogan, Daniel C., Darko, Samuel, Recordon-Pinson, Patricia, Dudoit, Yasmine, Llewellyn-Lacey, Sian, Chakrabarti, Lisa A., Buseyne, Florence, Migueles, Stephen A., Price, David A., Andreola, Marie-Aline, Satou, Yorifumi, Thiebaut, Rodolphe, Katlama, Christine, Autran, Brigitte, Douek, Daniel C., and Appay, Victor

Abstract

Human immunodeficiency virus 1 (HIV-1) infection is characterized by a dynamic and persistent state of viral replication that overwhelms the host immune system in the absence of antiretroviral therapy (ART). The impact of prolonged treatment on the antiviral efficacy of HIV-1-specific CD8+T cells has nonetheless remained unknown. Here, we used single-cell technologies to address this issue in a cohort of aging individuals infected early during the pandemic and subsequently treated with continuous ART. Our data showed that long-term ART was associated with a process of clonal succession, which effectively rejuvenated HIV-1-specific CD8+T cell populations in the face of immune senescence. Tracking individual transcriptomes further revealed that initially dominant CD8+T cell clonotypes displayed signatures of exhaustion and terminal differentiation, whereas newly dominant CD8+T cell clonotypes displayed signatures of early differentiation and stemness associated with natural control of viral replication. These findings reveal a degree of immune resilience that could inform adjunctive treatments for HIV-1.

Published
2024
Full Text
View/download PDF

35. HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial

Author

Vieillard, Vincent, Combadière, Béhazine, Tubiana, Roland, Launay, Odile, Pialoux, Gilles, Cotte, Laurent, Girard, Pierre-Marie, Simon, Anne, Dudoit, Yasmine, Reynes, Jacques, Rockstroh, Jürgen, Garcia, Felipe, Gatell, Jose, Devidas, Alain, Yazdanpanah, Yazdan, Weiss, Laurence, Fätkenheuer, Gerd, Autran, Brigitte, Joyeux, Delphine, Gharakhanian, Shahin, Debré, Patrice, and Katlama, Christine

Published
2019
Full Text
View/download PDF

37. Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg

Author

Touret, Franck, primary, Martin-Blondel, Guillaume, additional, de Lamballerie, Xavier, additional, Dupont, Axelle, additional, Izopet, Jacques, additional, Mentré, France, additional, Kamar, Nassim, additional, Autran, Brigitte, additional, Paintaud, Gilles, additional, Caillard, Sophie, additional, Richez, Christophe, additional, Couzi, Lionel, additional, Xhaard, Aliénor, additional, Marjanovic, Zora, additional, Avouac, Jerome, additional, Jacquet, Caroline, additional, Anglicheau, Dany, additional, Cheminant, Morgane, additional, Yazdanpanah, Yazdan, additional, N’Guyen, Stéphanie, additional, Terrier, Benjamin, additional, Gottenberg, Jacques Eric, additional, Besson, Caroline, additional, Letrou, Sophie, additional, Kali, Sabrina, additional, Angoulvant, Denis, additional, Barthélémy, Karine, additional, Priet, Stéphane, additional, Nurtop, Elif, additional, Sanchez, Ventzislava Petrov, additional, Tardivon, Coralie, additional, Blancho, Gilles, additional, Le Bourgeois, Amandine, additional, and Lévy, Vincent, additional

Published
2023
Full Text
View/download PDF

38. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

Author

Alidjinou, Enagnon Kazali, primary, Demaret, Julie, additional, Corroyer-Simovic, Bénédicte, additional, Vuotto, Fanny, additional, Miczek, Sophie, additional, Labreuche, Julien, additional, Goffard, Anne, additional, Trauet, Jacques, additional, Lupau, Daniela, additional, Dendooven, Arnaud, additional, Huvent-Grelle, Dominique, additional, Podvin, Juliette, additional, Dreuil, Daniel, additional, Faure, Karine, additional, Deplanque, Dominique, additional, Bocket, Laurence, additional, Duhamel, Alain, additional, Sobaszek, Annie, additional, Hober, Didier, additional, Hisbergues, Michael, additional, Puisieux, Francois, additional, Autran, Brigitte, additional, Yazdanpanah, Yazdan, additional, Labalette, Myriam, additional, and Lefèvre, Guillaume, additional

Published
2023
Full Text
View/download PDF

39. Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation

Author

de Lamballerie, Xavier, primary, Martin-Blondel, Guillaume, additional, Dupont, Axelle, additional, Izopet, Jacques, additional, Mentré, France, additional, Kamar, Nassim, additional, Autran, Brigitte, additional, Paintaud, Gilles, additional, Caillard, Sophie, additional, le Bourgeois, Amandine, additional, Richez, Christophe, additional, Couzi, Lionel, additional, Xhaard, Aliénor, additional, Marjanovic, Zora, additional, Avouac, Jerome, additional, Jacquet, Caroline, additional, Anglicheau, Denis, additional, Cheminant, Morgane, additional, Yazdanpanah, Yazdan, additional, Guyen, Stéphanie N, additional, Terrier, Benjamin, additional, Gottenberg, Jacques Eric, additional, Besson, Caroline, additional, Letrou, Sophie, additional, Kali, Sabrina, additional, Angoulvant, Denis, additional, Sanchez, Ventzislava Petrov, additional, Tardivon, Coralie, additional, Blancho, Gilles, additional, and Lévy, Vincent, additional

Published
2023
Full Text
View/download PDF

40. EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients

Author

Baron, Marine, primary, Labreche, Karim, additional, Bouzidi, Amira, additional, Veyri, Marianne, additional, Désiré, Nathalie, additional, Leblond, Véronique, additional, Coulet, Florence, additional, Boelle, Pierre-Yves, additional, Seck Thiam, Fatou, additional, Roos-Weil, Damien, additional, Charlotte, Frédéric, additional, Davi, Frederic, additional, Poullot, Elsa, additional, Rousseau, Alice, additional, Haioun, Corinne, additional, Spano, Jean-Philippe, additional, Autran, Brigitte, additional, Sylvain, Choquet, additional, and Guihot, Amélie, additional

Published
2022
Full Text
View/download PDF

46. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years

Author

Alidjinou, Enagnon Kazali, primary, Demaret, Julie, additional, Corroyer-Simovic, Bénédicte, additional, Labreuche, Julien, additional, Goffard, Anne, additional, Trauet, Jacques, additional, Lupau, Daniela, additional, Miczek, Sophie, additional, Vuotto, Fanny, additional, Dendooven, Arnaud, additional, Huvent-Grelle, Dominique, additional, Podvin, Juliette, additional, Dreuil, Daniel, additional, Faure, Karine, additional, Deplanque, Dominique, additional, Bocket, Laurence, additional, Duhamel, Alain, additional, Sobaszek, Annie, additional, Hober, Didier, additional, Hisbergues, Michael, additional, Puisieux, Francois, additional, Autran, Brigitte, additional, Yazdanpanah, Yazdan, additional, Labalette, Myriam, additional, and Lefèvre, Guillaume, additional

Published
2022
Full Text
View/download PDF

48. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

Author

Lambert-Niclot, S., George, E. C., Pozniak, A., White, E., Schwimmer, C., Jessen, H., Johnson, M., Dunn, D., Perno, C. F., Clotet, B., Plettenberg, A., Blaxhult, A., Palmisano, L., Wittkop, L., Calvez, V., Marcelin, A. G., Raffi, F., Dedes, Nikos, Chêne, Geneviève, Richert, Laura, Allavena, Clotilde, Raffi, François, Autran, Brigitte, Antinori, Andrea, Bucciardini, Raff aella, Vella, Stefano, Horban, Andrzej, Arribas, Jose, Babiker, Abdel G., Boffito, Marta, Pillay, Deenan, Pozniak, Anton, Franquet, Xavier, Schwarze, Siegfried, Grarup, Jesper, Chêne, Geneviève, Fischer, Aurélie, Richert, Laura, Wallet, Cédrick, Raffi, François, Diallo, Alpha, Molina, Jean-Michel, Saillard, Juliette, Moecklinghoff, Christiane, Stellbrink, Hans-Jürgen, Vella, Stefano, Van Leeuwen, Remko, Gatell, Jose, Sandstrom, Eric, Flepp, Markus, Babiker, Abdel G, Ewings, Fiona, George, Elizabeth C., Hudson, Fleur, Pozniak, Anton, Pearce, Gillian, Quercia, Romina, Rogatto, Felipe, Leavitt, Randi, Nguyen, Bach-Yen, Goebel, Frank, Marcotullio, Simone, Babiker, Abdel G., Ewings, Fiona, George, Elizabeth C., Hudson, Fleur, Kaur, Navrup, Sasieni, Peter, Spencer-Drake, Christina, Peto, Tim, Miller, Veronica, Allavena, Clotilde, Raffi, François, Vella, Stefano, Pozniak, Anton, Arnault, Fabien, Boucherie, Céline, Fischer, Aurélie, Jean, Delphine, Paniego, Observer Virginie, Paraina, Felasoa, Richert, Laura, Rouch, Elodie, Schwimmer, Christine, Soussi, Malika, Taieb, Audrey, Termote, Monique, Touzeau, Guillaume, Wallet, Cédrick, Babiker, Abdel G., Cursley, Adam, Dodds, Wendy, Ewings, Fiona, George, Elizabeth C., Hoppe, Anne, Hudson, Fleur, Kummeling, Ischa, Pacciarini, Filippo, Paton, Nick, Russell, Charlotte, Taylor, Kay, Ward, Denise, Aagaard, Bitten, Eid, Marius, Gey, Daniela, Jensen, Birgitte Gram, Grarup, Jesper, Jakobsen, Marie-Louise, Jansson, Per O., Jensen, Karoline, Joensen, Zillah Maria, Larsen, Ellen Moseholm, Pahl, Christiane, Pearson, Mary, Nielsen, Birgit Riis, Reilev, Søren Stentoft, Christ, Ilse, Lathouwers, Desiree, Manting, Corry, Van Leeuwen, Remko, Diallo, Alpha, Mendy, Bienvenu Yves, Metro, Annie, Saillard, Juliette, Couffin-Cadiergues, Sandrine, Knellwolf, Anne-Laure, Palmisiano, Lucia, Aznar, Esther, Barea, Cristina, Cotarelo, Manuel, Esteban, Herminia, Girbau, Iciar, Moyano, Beatriz, Ramirez, Miriam, Saiz, Carmen, Sanchez, Isabel, Yllescas, Maria, Binelli, Andrea, Colasanti, Valentina, Massella, Maurizio, Palmisiano, Lucia, Anagnostou, Olga, Gioukari, Vicky, Touloumi, Giota, Schmied, Brigitte, Rieger, Armin, Vetter, Norbert, De Wit, Stephane, Florence, Eric, Vandekerckhove, Linos, Gerstoft, Jan, Mathiesen, Lars, Katlama, Christine, Cabie, Andre, Cheret, Antoine, Dupon, Michel, Ghosn, Jade, Girard, Pierre-Marie, Goujard, Cécile, Lévy, Yves, Molina, Jean-Michel, Morlat, Philippe, Neau, Didier, Obadia, Martine, Perre, Philippe, Piroth, Lionel, Reynes, Jacques, Tattevin, Pierre, Raffi, François, Ragnaud, Jean Marie, Weiss, Laurence, Yazdan, Yazdanpanah, Yeni, Patrick, Zucman, David, Behrens, Georg, Esser, Stefan, Fätkenheuer, Gerd, Hoffmann, Christian, Jessen, Heiko, Rockstroh, Jürgen, Schmidt, Reinhold, Stephan, Christoph, Unger, Stefan, Hatzakis, Angelos, Daikos, George L., Papadopoulos, Antonios, Skoutelis, Athamasios, Banhegyi, Denes, Mallon, Paddy, Mulcahy, Fiona, Antinori, Andrea, Andreoni, Massimo, Bonora, Stefano, Castelli, Francesco, Monforte, Antonella DʼArminio, Di Perri, Giovanni, Galli, Massimo, Lazzarin, Adriano, Mazzotta, Francesco, Carlo, Torti, Vullo, Vincenzo, Prins, Jan, Richter, Clemens, Verhagen, Dominique, Van Eeden, Arne, Horban, Andrzej, Doroana, Manuela, Antunes, Francisco, Maltez, Fernando, Sarmento-Castro, Rui, Garcia, Juan Gonzalez, Aldeguer, José López, Clotet, Bonaventura, Domingo, Pere, Gatell, Jose M., Knobel, Hernando, Marquez, Manuel, Miralles, Martin Pilar, Portilla, Joaquin, Soriano, Vicente, Tellez, Maria-Jesus, Thalme, Anders, Blaxhult, Anders, Gisslen, Magnus, Winston, Alan, Fox, Julie, Gompels, Mark, Herieka, Elbushra, Johnson, Margaret, Leen, Clifford, Pozniak, Anton, Teague, Alastair, Williams, Ian, Boyd, Mark Alastair, Grarup, Jesper, Jansson, Per O., Møller, Nina Friis, Larsen, Ellen Frøsig Moseholm, Morlat, Philippe, Piroth, Lionel, Le Moing, Vincent, Wit, Ferdinand W. N. M., Kowalska, Justyna, Berenguer, Juan, Moreno, Santiago, Müller, Nicolas J., Török, Estée, Post, Frank, Angus, Brian, Calvez, Vincent, Boucher, Charles, Collins, Simon, Dunn, David, Lambert, Sidonie, Marcelin, Anne-Geneviève, Perno, Carlo Federico, Pillay, Deenan, White, Ellen, Boffito, Marta, Ammassari, Adriana, Antinori, Andrea, Stoehr, Wolgang, Autran, Brigitte, Schmidt, Reinhold Ernst, Odermarsky, Michal, Smith, Colette, Thiébaut, Rodolphe, Arribas, Jose, De La Serna, Jose Ignacio Bernardino, Castagna, Antonella, De Wit, Stephane, Franquet, Xavier, Furrer, Hans-Jackob, Katlama, Christine, Mocroft, Amanda, Reiss, Peter, Bucciardini, Raffaella, Dedes, Nikos, Fragola, Vincenzo, George, Elizabeth C., Lauriola, Marco, Murri, Rita, Nieuwkerk, Pythia, Spire, Bruno, Volny-Anne, Alain, West, Brian, Amieva, Hélène, Antinori, Andrea, Llibre Codina, Josep Maria, Richert, Laura, Stoehr, Wolgang, Winston, Alan, Castelli, Francesco, Braggion, Marco, and Focà, Emanuele

Published
2016
Full Text
View/download PDF

50. Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

Author

Supervie, V, Assoumou, L, Breban, R, Lert, F, Costagliola, D, Pialoux, G, Landman, R, Girard, P. M, Slama, L, Cabié, André, Abel, Sylvie, Hochedez, Patrick, Pierre-François, Sandrine, Rozé, Benoît, Simon, Anne, Lupin, Catherine, Katlama, Christine, Valentin, Marc Antoine, Autran, Brigitte, Samri, Assia, Lambert, Sidonie, Marcelin, Anne Geneviève, Landman, Roland, Joly, Véronique, Julia, Zélie, Harent, Stanislas, Papot, Emmanuelle, Phung, Bao-Chau, Peytavin, Gilles, Minh, Patrick Lê, Rami, Agathe, Diemer, Myriam, Parrinello, Maguy, Cahitte, Isabelle, Zeng, Feng, Mortier, Emmanuel, Pialoux, Gilles, L’Yavanc, Thomas, Le Loup, Guillaume, Bonnard, Philippe, Lebrette, Marie Gisèle, Chas, Julie, Berrebi, Valérie, Velazquez, Nadège, Adda, Anne, Duvivier, Claudine, Touam, Fatima, Lortholary, Olivier, Shoai-Tehrani, Michka, Rouzaud, Claire, Denes, Eric, Ducroux-Roubertou, Sophie, Durox, Hélène, Genet, Claire, Rogez, Jean-Philippe, Rogez, Sylvie, Pascual, Jose, Weiss, Laurence, Pavie, Juliette, Bourzam, Erila, Aumaître, Hugues, Ferreyra, Milagros, Saada, Matthieu, Malet, Martine, Palacios, Christia, Honore, Patricia, Zamord, Irene, Berthe, Huguette, Landowski, Stéphanie, de Truchis, Pierre, Perre, Philippe, Girard, Pierre-Marie, Valin, Nadia, Campa, Pauline, Lefebvre, Bénédicte, Meynard, Jean-Luc, Pauchard, Michèle, and Surgers, Laure

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results